Micell has announced the commercial availability of the MiStent sirolimus-eluting absorbable polymer coronary stent system in Europe. Stentys, Micell’s distribution partner in Paris, plans a controlled launch in Western Europe followed by a full commercial launch for the second half of 2015 in selected countries within Europe, Middle East, South-East Asia and Latin America.
Arthur J Benvenuto, chairman and chief executive officer of Micell said, “Patients with cardiovascular disease and their physicians now have access to a new class of drug-eluting stent that allows the drug to remain in the tissue for an extended period–well beyond a rapidly-absorbing polymer. This performance feature is unique to MiStent and until now, has been largely impossible. Most importantly, it has translated into meaningful clinical benefits.”
MiStent has received CE mark in the European Union, and will be distributed exclusively by Stentys around the world, with the exception of the USA, Canada, China, South Korea and Japan. Micell is in the process of expanding its manufacturing capabilities through its partner, Surgical Technologies, based in St. Paul, Minnesota, USA.